Protalix (PLX) AI Stock Analysis

• Market Cap: $139.13M
• Dividend Yield: N/A
• Average Volume (3M): 532.74K
• Price to Earnings (P/E): 24.9
• Beta (1Y): 0.51
• Revenue Growth: 35.42%
• EPS Growth: N/A
• Country: US
• Employees: 213
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.03
• Shares Outstanding: 80,421,180
• 10 Day Avg. Volume: 498,619
• 30 Day Avg. Volume: 532,740
• PEG Ratio: -0.70
• Price to Book (P/B): 3.16
• Price to Sales (P/S): 2.55
• P/FCF Ratio: 18.45
• Enterprise Value/Market Cap: 1.14
• Enterprise Value/Revenue: 2.56
• Enterprise Value/Gross Profit: 4.45
• Enterprise Value/Ebitda: 17.84
• 1Y Price Target: $12.00
• Price Target Upside: 570.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.12
• Revenue Forecast (FY): $61.97M

• Rating: 55 Neutral
• Price Target: $2.00 ▲(11.73% Upside)

Protalix's stock score is primarily influenced by its financial performance improvements and positive earnings call highlights. However, technical analysis indicates bearish momentum, and recent corporate events pose regulatory challenges, impacting the overall score.

Positive Factors

Revenue Growth

The 24% revenue growth year-to-date indicates strong demand for Protalix's products, supporting long-term business expansion and stability.

Cash Position

A strong cash position ensures operational stability and provides the financial flexibility to invest in growth opportunities and R&D.

Clinical Trial Advancement

Advancement in clinical trials, such as PRX-115, positions Protalix to expand its product pipeline, enhancing long-term growth prospects.

Negative Factors

Regulatory Challenges

Pending regulatory decisions on Elfabrio's dosing regimen may hinder market expansion in Europe, affecting future revenue streams.

Inconsistent Revenue Growth

A decline in quarterly revenue highlights potential volatility in sales, which could impact financial predictability and investor confidence.

Rising R&D Expenses

Increased R&D expenses, while necessary for growth, can pressure short-term profitability and require careful financial management.

Protalix Business Overview & Revenue Model

Company Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

How the Company Makes Money

Protalix generates revenue primarily through the sale of its products, notably Elelyso, which is marketed in collaboration with partners such as Pfizer. The company earns revenue from product sales, licensing agreements, and potential royalties from its collaborative partners. Additionally, Protalix may engage in research and development agreements with other companies or institutions, providing another revenue stream. Their financial performance is influenced by the successful commercialization of their therapies and the achievement of milestones in partnerships.

Protalix Financial Statement Overview

Summary

Protalix has shown significant improvement in profitability and cash flow generation, which are crucial for its financial stability. However, inconsistent revenue growth and high leverage remain concerns.

Income Statement

The company has demonstrated a positive turnaround in profitability over the last few years. Gross profit margins have been healthy, and there was a notable improvement in net income, moving from losses to profits recently. However, revenue growth has been inconsistent with a decline in the latest period, and EBIT margins are still relatively low, indicating room for operational improvements.

Balance Sheet

Protalix's balance sheet shows a significant reduction in total debt, which is a positive sign for financial health. The equity position has improved from negative to positive, enhancing the equity ratio. However, the debt-to-equity ratio is still high, indicating potential leverage risks. The company needs to continue strengthening its equity to mitigate these risks further.

Cash Flow

The company has shown a strong improvement in cash flow, moving from negative free cash flow to positive in the latest period. The operating cash flow to net income ratio indicates a healthy conversion of profits into cash. However, the free cash flow growth rate is volatile, suggesting potential fluctuations in cash generation capabilities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	61.84M	53.40M	65.49M	47.64M	38.35M	62.90M
Gross Profit	35.58M	29.08M	42.51M	28.05M	22.00M	52.02M
EBITDA	8.87M	6.52M	12.94M	-10.78M	-18.94M	4.45M
Net Income	5.39M	2.93M	8.31M	-14.93M	-27.58M	-6.52M
Balance Sheet
Total Assets	82.26M	73.42M	84.43M	55.79M	73.67M	67.93M
Cash, Cash Equivalents and Short-Term Investments	29.37M	34.83M	44.56M	22.18M	38.98M	38.55M
Total Debt	8.18M	5.53M	27.69M	33.47M	33.47M	64.40M
Total Liabilities	29.36M	30.21M	50.87M	66.43M	79.70M	94.97M
Stockholders Equity	52.91M	43.21M	33.57M	-10.64M	-6.04M	-27.04M
Cash Flow
Free Cash Flow	-11.69M	7.39M	-2.47M	-25.63M	-11.74M	-26.76M
Operating Cash Flow	-10.03M	8.67M	-1.32M	-25.00M	-10.29M	-26.11M
Investing Cash Flow	-16.57M	4.22M	-16.71M	-5.04M	18.92M	-19.95M
Financing Cash Flow	12.81M	-16.79M	24.67M	8.24M	12.08M	46.47M

Protalix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLX, the sentiment is Negative. The current price of 1.79 is above the 20-day moving average (MA) of 1.76, below the 50-day MA of 2.02, and below the 200-day MA of 1.95, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 41.52 is Neutral, neither overbought nor oversold. The STOCH value of 39.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PLX.

Protalix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	55 Neutral	$139.13M	24.89	12.64%	―	35.42%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IPHA	49 Neutral	$166.49M	-3.00	-271.32%	―	-75.77%	-31.24%
CHRS	47 Neutral	$164.38M	-0.88	―	―	-72.54%	-19972.15%
SLS	43 Neutral	$336.16M	-9.20	-84.33%	―	―	59.04%
TARA	39 Underperform	$272.09M	-3.75	-49.42%	―	―	48.84%
FBRX	36 Underperform	$371.92M	-6.60	-110.72%	―	―	77.08%

Protalix Corporate Events

Protalix Seeks EMA Re-examination for Elfabrio Dosing

On November 3, 2025, Protalix BioTherapeutics and Chiesi Global Rare Diseases announced their request for a re-examination of the European Medicines Agency’s negative opinion on the proposed dosing regimen for Elfabrio, a treatment for Fabry disease. The existing marketing authorization for Elfabrio remains in effect while the re-examination is underway, highlighting the companies’ commitment to addressing the needs of the Fabry community.

Protalix Faces EMA Setback on Elfabrio® Dosing

On October 17, 2025, Protalix BioTherapeutics and its partner Chiesi Global Rare Diseases announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the proposed dosing regimen for Elfabrio®. This decision may impact the company’s market strategy and regulatory approach for Elfabrio® in Europe, potentially affecting stakeholders and future commercial plans.